4//SEC Filing
Lloyd-Smith Malcolm 4
Accession 0001209191-22-046070
CIK 0000914475other
Filed
Aug 15, 8:00 PM ET
Accepted
Aug 16, 6:44 PM ET
Size
20.7 KB
Accession
0001209191-22-046070
Insider Transaction Report
Form 4
Lloyd-Smith Malcolm
Chief Regulatory Officer
Transactions
- Exercise/Conversion
Incentive Stock Option
2022-08-15$43.24/sh−3,361$145,330→ 0 totalExercise: $43.24Exp: 2027-02-06→ Common Stock (3,361 underlying) - Exercise/Conversion
Common Stock
2022-08-12$35.99/sh+21,533$774,973→ 40,421 total - Exercise/Conversion
Common Stock
2022-08-15$35.99/sh+3,455$124,345→ 22,343 total - Sale
Common Stock
2022-08-12$105.95/sh−21,533$2,281,331→ 18,888 total - Exercise/Conversion
Common Stock
2022-08-15$81.49/sh+1,227$99,988→ 26,931 total - Exercise/Conversion
Common Stock
2022-08-15$43.24/sh+3,361$145,330→ 25,704 total - Exercise/Conversion
Non-Qualified Stock Option
2022-08-12$35.99/sh−21,533$774,973→ 0 totalExercise: $35.99Exp: 2026-02-05→ Common Stock (21,533 underlying) - Exercise/Conversion
Incentive Stock Option
2022-08-15$35.99/sh−3,455$124,345→ 0 totalExercise: $35.99Exp: 2026-02-05→ Common Stock (3,455 underlying) - Exercise/Conversion
Incentive Stock Option
2022-08-15$81.49/sh−1,227$99,988→ 0 totalExercise: $81.49Exp: 2028-02-05→ Common Stock (1,227 underlying)
Footnotes (6)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.28 to $106.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Includes an aggregate of 157 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- [F4]Option granted February 05, 2016 and vested monthly over four years.
- [F5]Option granted February 06, 2017 and vested monthly over four years
- [F6]Option granted February 05, 2018 and vested monthly over four years
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001557146
Filing Metadata
- Form type
- 4
- Filed
- Aug 15, 8:00 PM ET
- Accepted
- Aug 16, 6:44 PM ET
- Size
- 20.7 KB